Viking Therapeutics Inc (VKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.73B
Last updated: Nov 17, 2026 at 4:43 PM ET
Viking Therapeutics Inc (VKTX) Statistics
Viking Therapeutics (VKTX) has a market cap of $3.73B and an enterprise value of $3.30B. Its share count is up 5.10% from a year earlier. It holds $426.95M more cash than debt, 11.46% of its market cap.
Total Valuation
Enterprise value is 11.46% below the market cap, as cash exceeds debt.
| Market Cap | $3.73B |
|---|---|
| Enterprise Value | $3.30B |
| Latest price (Nov 17, 2026) | $26.88 |
Key Dates
The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 31.27% over 52 weeks and trades 7.41% below its 50-day average.
| Beta (1Y) | 1.36 |
|---|---|
| 52-Week Change | -31.27% |
| 1-Month Change | +7.31% |
| 3-Month Change | -25.29% |
| 6-Month Change | -5.35% |
| 5-Year Change | +368.73% |
| 10-Year Change | +2449.53% |
| Total Return (1Y) | -31.27% |
| Total Return (3Y CAGR) | +33.60% |
| Total Return (5Y CAGR) | +36.25% |
| Return vs SPY (1Y) | -40.37% |
| Max Drawdown (1Y) | -42.54% |
| Max Drawdown (3Y) | -78.86% |
| Sharpe Ratio (1Y) | -0.51 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $29.03 |
| 200-Day Average | $32.14 |
| 52-Week Range | $23.82 to $43.10 |
| RSI (14 Days) | 47.2 |
| Average Volume (20 Days) | 4.18M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.27x current liabilities, and total debt is 0.43x shareholder equity.
| Current Ratio | 7.27x |
|---|---|
| Quick Ratio | 7.27x |
| Debt / Equity | 0.43x |
Returns and Efficiency
Return on invested capital is -61.05% over the last 12 months, against a 5-year average of -48.62%.
| Return on Equity (ROE) | -106.56% |
|---|---|
| Return on Assets (ROA) | -64.19% |
| Return on Invested Capital (ROIC) | -61.05% |
| ROE (5Y Average) | -33.61% |
| ROA (5Y Average) | -30.53% |
| ROIC (5Y Average) | -48.62% |
Scores
VKTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$94.00K |
| Operating Income | -$648.57M |
| Pretax Income | -$627.18M |
| Net Income | -$627.20M |
| Reported EPS (TTM) | -$5.40 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 60.24% of the $977.17M in total assets.
| Cash and Equivalents | $677.61M |
|---|---|
| Total Debt | $250.66M |
| Net Cash | $426.95M |
| Net Cash Per Share | $3.62 |
| Working Capital | $839.10M |
| Shareholder Equity | $588.60M |
| Book Value Per Share | $4.99 |
| Total Assets | $977.17M |
| Total Liabilities | $388.57M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$462.63M |
|---|---|
| FCF Per Share | -$3.64 |
| Depreciation and Amortization | $4.21M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +26.91% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +26.91% |
Dividends and Yields
VKTX does not pay a dividend.
| Buyback Yield | -9.47% |
|---|---|
| Shareholder Yield | -9.47% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VKTX
What is VKTX's market cap?
Viking Therapeutics has a market cap of $3.73B. Its enterprise value, which adds debt and subtracts cash, is $3.30B.
How many shares of VKTX are outstanding?
Viking Therapeutics has 118.05M shares outstanding. The count is up 5.10% from a year earlier.
Does VKTX pay a dividend?
No. Viking Therapeutics does not pay a dividend.
How much debt does VKTX have?
Viking Therapeutics has $250.66M of total debt and $677.61M of cash and equivalents, a net cash position of $426.95M.
VKTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors